Ficlatuzumab
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6446H9954N1718O2026S46 |
| Molar mass | 145409.30 g·mol−1 |
  | |
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[2]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- "AVEO Releases Phase 2 Data", Drug Discovery & Development, dddmag.com, May 3, 2012, retrieved June 3, 2012
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.